Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview

Luigi Elio Adinolfi, Riccardo Nevola, Giacomo Lus, Luciano Restivo, Barbara Guerrera, Ciro Romano, Rosa Zampino, Luca Rinaldi, Ausilia Sellitto, Mauro Giordano, Aldo Marrone

Luigi Elio Adinolfi, Clinical Hospital of Marcianise, Second University of Naples, 81025 Marcianise (CE), Italy
Luigi Elio Adinolfi, Riccardo Nevola, Luciano Restivo, Barbara Guerrera, Ciro Romano, Rosa Zampino, Luca Rinaldi, Ausilia Sellitto, Mauro Giordano, Aldo Marrone, Department of Medical, Surgical, Neurological, Geriatric, and Metabolic Sciences, Second University of Naples, 80100 Naples, Italy
Giacomo Lus, Neurological Sciences, Second University of Naples, 80100 Naples, Italy

Author contributions: Adinolfi LE and Nevola R conceived, drafted the article, and approved the final version; Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A and Marrone A conceived the paper, reviewed the literature, and approved the final version of this article; Lus G and Giordano M critically reviewed the manuscript and approved the final version of this article.

Supported by Research grant from Regione Campania, Italy.
Conflict-of-interest: All authors have no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Luigi Elio Adinolfi, MD, Professor, Director of Internal Medicine, Clinical Hospital of Marcianise, Second University of Naples, ASL Caserta, Rione Santella, 81025 Marcianise (CE), Italy. luigi.e.adinolfi@unina2.it
Telephone: +39-823-690642
Fax: +39-823-690642
Received: October 1, 2014
Peer-review started: October 3, 2014
First decision: October 29, 2014
Revised: November 11, 2014
Accepted: January 8, 2015
Article in press: January 8, 2015
Published online: February 28, 2015

Abstract
Hepatitis C virus (HCV) infection is considered a systemic disease because of involvement of other organs and tissues concomitantly with liver disease. Among the extrahepatic manifestations, neuropsychiatric disorders have been reported in up to 50% of chronic HCV infected patients. Both the central and peripheral nervous system may be involved with a wide variety of clinical manifestations. Main HCV-associated neurological conditions include cerebrovascular events, encephalopathy, myelitis, encephalomyelitis, and cognitive impairment, whereas “brain fog”, depression, anxiety, and fatigue are at the top of the list of psychiatric disorders. Moreover, HCV infection is known to cause both motor and sensory peripheral neuropathy in the context of mixed cryoglobulinemia, and has also been recently recognized as an independent risk factor for stroke. These extrahepatic manifestations are independent of severity of the underlying chronic liver disease and hepatic encephalopathy. The brain is a suitable site for HCV replication, where the virus may directly exert neurotoxicity; other mechanisms proposed to explain the pathogenesis of neuropsychiatric disorders in chronic HCV infection include derangement of metabolic pathways of infected cells, alterations in neurotransmitter circuits, autoimmune disorders, and cerebral or systemic inflammation. A pathogenic role for HCV is also suggested by improvement of neurological and psychiatric symptoms in patients achieving a sustained virologic response following interferon treatment; however, further ad hoc trials are needed to fully assess the impact of HCV infection and specific antiviral treatments on associated neuropsychiatric disorders.

Key words: Hepatitis C virus; Neurological disorders; Psychiatric disorders; Stroke; Inflammation
HCV-associated extrahepatic conditions may result in a wide variety of clinical manifestations capable to aggravate the clinical spectrum of hepatic infection or to even dominate the clinical scenario, regardless of liver disease manifestations. Thus, it is important for clinicians to maintain an updated knowledge of the role of HCV as causative agent in extrahepatic manifestations in order to establish a timely diagnosis and proper treatment.

Chronic hepatitis C has been reported to be associated with neurological and psychiatric disorders in up to 50% of the cases. Different pathogenic mechanisms underlie such alterations. Main HCV-associated neurological conditions include cerebrovascular events, autoimmune disorders, encephalopathy syndromes, myelitis, encephalomyelitis, and cognitive impairment; psychiatric disorders include depression, anxiety, and fatigue. Of importance, these disorders do not seem to correlate with severity of the underlying chronic liver disease and are independent of hepatic encephalopathy. If a link exists between HCV and brain damage, current knowledge seems to suggest, at least in part, a direct role for the virus. Indeed, the brain is a suitable site for HCV replication; intriguingly, viral sequence diversity between brain and liver tissue has been reported, possibly suggesting independent HCV evolution in the central nervous system (CNS).

The aim of this paper was to review the current knowledge on neurological and psychiatric conditions associated with chronic HCV infection, the presumed underlying pathogenic mechanisms, and the effects of antiviral treatment.

**HCV infection and neurological diseases**

Several neurological disorders, due to involvement of the central and/or peripheral nervous system, have been described in association with chronic HCV infection.

**HCV infection and cerebrovascular events**

In chronic HCV infection, cerebrovascular acute and chronic events have been reported with a higher prevalence than that observed in the general population; in many cases, such neurologic conditions were associated with the presence of mixed cryoglobulinemia. Enger et al., in the largest retrospective study to date, including 21919 HCV-positive subjects and 67109 HCV-negative control subjects, reported a strict association between HCV and stroke, with a higher adjusted estimated risk of stroke for anti-HCV positive subjects [odds ratio (OR) = 1.76; 95%CI: 1.23-2.52]. Gutierrez et al. showed a close association between HCV infection and stroke (OR = 9.61; 95%CI: 2.51-35.78) in a retrospective study of subjects from the NHANES cohort during the period 2005-2010. However, it should be underscored that the two above studies have thus far been published only in an abstract form.
Accordingly, viral load as well as HCV-related steatosis, which result from modulation of atherogenic factors, has been reported as independent risk factors for early and facilitated carotid atherosclerosis. Besides, HCV-induced mitochondrial injury may increase production of reactive oxygen species, which are known to contribute to development and progression of atherosclerosis. The close correlation between HCV RNA serum levels and risk of cerebrovascular death lends support to the notion of a stronger inflammatory response ensuing from host-virus interaction, leading to a more accelerated and severe atherosclerosis.

Occlusive cerebral vascular diseases can also occur in the context of HCV-related vasculitis, such as mixed cryoglobulinemia, antiphospholipid syndrome, and ANCA-associated vasculitis. HCV-related mixed cryoglobulinemia is due to precipitation of complement-fixing immune complexes in vessel walls, with involvement of such small vessels as vasa nervorum and cerebral arterioles. Consistently, involvement of the white substance has been reported, manifesting as acute or sub-acute encephalopathy syndrome. Confusion, cognitive impairment, dysarthria and dysphagia can generally be observed, often in association with multi-infarct encephalopathy, likely due to small ischemic lesions leading to chronic hypoperfusion of subcortical regions and periventricular white matter. In addition, it should not be overlooked that HCV infection may increase the risk of atherosclerosis and earlier stroke through predisposition to such metabolic diseases as type 2 diabetes, prevalently by inducing insulin-resistance. Indeed, HCV has been shown to affect glucose-insulin homeostasis as well as lipid metabolism and lipid synthesis in an atherogenic fashion.

How HCV may predispose to ischemic stroke is unclear. Carotid plaque destabilization with subsequent rupture and erosion plays a crucial role in the development of 20%-30% of all cases of ischemic stroke. In this regard, the causal association between chronic HCV infection and atherosclerosis is well documented. Inflammation is the key mediator of plaque rupture and thromboembolism. Consistently, chronic HCV infection is characterized by a state of chronic inflammation, which may be instrumental in the pathogenesis of arterial remodeling. Infection may cause atherosclerosis by building up a cascade of immune/inflammatory responses either locally (within vascular tissue) or systemically (through inflammatory mediators). Indeed, HCV core protein positivity has been shown to independently predict development of carotid plaques; specifically, individuals testing positive for HCV core protein had a 5.6 fold higher risk of developing carotid plaques than HCV-negative patients. Moreover, HCV has been demonstrated to colonize and replicate within carotid plaques. Of particular interest was the discovery of HCV RNA negative strain sequences in plaque tissue, suggesting active infection locally, and, presumably, an active role in carotid atherosclerosis through vascular inflammation and consequent plaque instability. Accordingly, viral load as well as HCV-related steatosis, which result from modulation of atherogenic factors, has been reported as independent risk factors for early and facilitated carotid atherosclerosis. Besides, HCV-induced mitochondrial injury may increase production of reactive oxygen species, which are known to contribute to development and progression of atherosclerosis. The close correlation between HCV RNA serum levels and risk of cerebrovascular death lends support to the notion of a stronger inflammatory response ensuing from host-virus interaction, leading to a more accelerated and severe atherosclerosis.

Occlusive cerebral vascular diseases can also occur in the context of HCV-related vasculitis, such as mixed cryoglobulinemia, antiphospholipid syndrome, and ANCA-associated vasculitis. HCV-related mixed cryoglobulinemia is due to precipitation of complement-fixing immune complexes in vessel walls, with involvement of such small vessels as vasa nervorum and cerebral arterioles. Consistently, involvement of the white substance has been reported, manifesting as acute or sub-acute encephalopathy syndrome. Confusion, cognitive impairment, dysarthria and dysphagia can generally be observed, often in association with multi-infarct encephalopathy, likely due to small ischemic lesions leading to chronic hypoperfusion of subcortical regions and periventricular white matter. In addition, it should not be overlooked that HCV infection may increase the risk of atherosclerosis and earlier stroke through predisposition to such metabolic diseases as type 2 diabetes, prevalently by inducing insulin-resistance. Indeed, HCV has been shown to affect glucose-insulin homeostasis as well as lipid metabolism and lipid synthesis in an atherogenic fashion.

Recently, all of the known HCV receptor molecules (LDLR, CD81, claudin-1, occludin, and scavenger receptor-B1) have been reported to be expressed on the surface of blood-brain barrier endothelial cells; within these cells, HCV replication has also been documented. Based on these observations, HCV can theoretically cause obstructive vascular disorders per se, i.e., by direct involvement of brain vessels through chronic inflammation.

HCV infection and CNS inflammatory disorders

CNS involvement in chronic HCV infection may also result from encephalic and/or meningeal inflammation. Cases of leukoencephalitis associated with HCV infection have been reported. Different clinical patterns have been described, ranging from a rapidly evolving form with perivascular T cells infiltrates and microglial nodules to progressive encephalomyelitis associated with neuronal loss and perivascular lymphocyte infiltrates. Spastic quadriaparesis, spinicter dysfunction, and sensory loss have been reported to dominate the clinical scenario. As HCV genome in brain tissue has been reportedly detected at post-mortem evaluation, a possible correlation may be theorized.
Evidence of an association between HCV and transverse myelitis, with attending motor, sensitive, and autonomic dysfunction has been reported\[52\-55\]. Acute demyelination, with parenchymal and perivascular T cell infiltration, has been described on pathological analysis of spinal cord biopsy. Disease onset may be characterized by symptoms indicative of transverse myelitis or acute partial transverse myelopathy, or else by spastic paraplegia or sensory ataxia. A recurrent course and multisegmental spinal involvement have been frequently reported. Since these cases tested positive for anti-HCV antibodies in the liquor, with no evidence of virus in tissue biopsies, an immune-mediated pathogenesis was hypothesized to explain disease pathogenesis.

Acute disseminated encephalomyelitis has also been reported in association with hepatitis C infection\[56\,57\]. Magnetic resonance imaging findings included multiple foci of CNS damage, prevalently, but not exclusively, in the cerebral and cerebellar white matter. Clinically, alterations of consciousness, psychomotor agitation, hemiparesis, hemianopsia, urinary retention, and other focal neurological defects have been described. HCV has been suggested to trigger demyelination through immune-mediated mechanisms, as also inferred by the beneficial effect of steroid therapy. These observations suggest that in patients with acute disseminated encephalomyelitis the possibility of HCV infection should not be overlooked.

HCV infection and cognitive disorders

Several studies have reported heterogeneous neuropsychological deficits in chronic HCV infected patients, including inadequate concentration and working memory speed, impaired ability of sustained attention, decreased psychomotor speed\[58\-61\]. Nearly one-third of HCV-positive patients can be diagnosed with cognitive disorders, generally of mild degree. Individuals with poor cognitive reserve appear to be particularly susceptible to virus-induced neurocognitive impairment\[62\]. Failure in domains depending upon front striatal systems, including fine motor speed\[63\], learning\[64\] and information processing efficiency\[99\], may underlie neurocognitive disorders. An association between HCV and impairment of a range of executive functions, including reasoning, abstraction, mental flexibility\[62\,63\] and verbal response inhibition\[65\,66\], has also been described. Fontana et al\[67\] mainly reported alterations in verbal recall and working memory in 33% of HCV-positive patients with advanced fibrosis. Depression scores were predictive of cognitive impairment\[65\]. In addition, using neurophysiological tests, like P300 event-related potentials, delayed latency peaks and reduced amplitudes have been disclosed in cognitively impaired HCV-positive individuals\[66\].

A recent population-based cohort study was conducted to investigate the risk of dementia in chronic HCV-infected patients\[68\]. A total of 58570 HCV-infected and uninfected matched pairs were enrolled. During a follow-up period of 533861 person-years the incidence rates of dementia was for HCV and non-HCV of 56.0 and 47.7 cases per 10000 person-years, respectively (\(P < 0.05\)) and the adjusted HR was 1.36 (95%CI: 1.27-1.42) for HCV patients. The results indicate that HCV might increase the risk for dementia; however, the data, although obtained in a large cohort, need to be confirmed in different population settings.

Despite the large body of evidence on the possible relationship between HCV infection and neurologic disorders, studies not confirming such an association also exist. Hilsabeck et al\[59\] did not find a different pattern of cognitive deficits between patients with chronic hepatitis C and those with chronic liver disease of different etiology. In spite of some degree of quality of life impairment, Córdoba et al\[69\] recorded normal neuropsychiatric performance in 40 non-cirrhotic HCV-positive patients, when compared with healthy subjects. Similarly, Abrantes et al\[99\] found no evidence of an association between HCV infection and cognitive impairment. However, the small number of subjects examined in the above studies may have affected result interpretation.

HCV infection and peripheral neuropathy disorders

In contrast to the brain, there is currently no evidence for peripheral nerves as permissive sites for HCV replication; however, a wide variety of motor, sensory or sensorimotor mono- or polyneuropathies has been described during chronic HCV infection. Most peripheral neuropathies have been reported in patients with HCV-related mixed cryoglobulinemia, with prevalence up to 86% of cases\[60\]. In particular, a sensory motor peripheral neuropathy has been found in up to 30% of HCV-positive cryoglobulinemic patients\[71\,73\]. Such neuropathy is the consequence of ischemic nerve changes, secondary to small-vessel vasculitis or necrotizing arteritis of medium-sized vessels\[74\]. Frequently, the clinical onset is subacute as a distal, symmetric, sensory or sensorimotor polyneuropathy, although asymmetrical sensory impairment has also been reported\[75\,76\]. Small fiber sensory polyneuropathy (SFSN), a painful condition mainly characterized by burning feet and tingling, is the most frequent neuropathy observed in patients with mild cryoglobulinemia syndrome, whereas the so-called large fiber sensory neuropathy (LFSN) has been described less frequently\[77\]. HCV-associated restless legs syndrome has also been reported as expression of SFSN\[78\,79\]. SFSN may later evolve in LFSN. LFSN symptoms include sensory loss, paresthesias, numbness, and cramps\[80\].

As mentioned above, the pathogenesis of cryoglobulinemia-related neuropathy is likely due to nerve ischemia secondary to occlusion or vasculitis of the vasa nervorum\[74\,81\], causing fascicular ischemia and axonal degeneration\[82\,84\]. T cell dependent
mechanisms have been documented to be responsible for epineural inflammation\(^{[85]}\). Thus, HCV-related peripheral neuropathy seems to be the result of virus-triggered immune-mediated mechanisms\(^{[86,87]}\). It remains unclear whether deposition of cryoglobulin plays a direct pathogenic role during damage of the vasa nervorum or whether it simply represents an epiphenomenon of the immune response.

Neuropathy has also been reported in HCV patients without cryoglobulinemia\(^{[88,89]}\), although with a lower prevalence (9% vs 45%, without and with cryoglobulinemia, respectively) and less severity\(^{[71,84]}\). Likewise, immune-mediated mechanisms have been proposed to explain vascular and perivascular inflammation leading to ischemia and fascicular axonal loss\(^{[90,91]}\).

Unusual forms of neuropathy have also been reported, such as mononeuritis multiplex with necrotizing vasculitis of medium sized vessels\(^{[92]}\), motor polyneuropathies\(^{[93]}\), and autonomic neuropathy\(^{[94]}\). In addition, sporadic cases of HCV-related demyelinating peripheral neuropathy have been reported, displaying clinically heterogeneous features, including sensory ataxia\(^{[95]}\), Lewis-summner syndrome\(^{[96]}\), and chronic inflammatory demyelinating polyradiculoneuropathy\(^{[97,98]}\).

### HCV infection and psychiatric disorders

Psychiatric symptoms such as “brain fog”, fatigue, weakness, depression, and anxiety have been reported with high frequency in patients with chronic HCV infection, causing interference with patient ability to perform daily activities and impairment of quality of life\(^{[99-107]}\). Mere knowledge of HCV serological status is itself an important reason for poor health-related quality of life\(^{[108,109]}\), due to impairment of intimate and family relationships, changes in dietary habits, reduced sense of well-being because of fear of contagion and prognosis, social marginalization, fatigue, anger, hopelessness, depression, and stigma\(^{[110]}\). Moreover, the possible relation between HCV and psychiatric disorders is further strengthened by the results of studies comparing health-related quality of life between HBV and HCV patients. Specifically, a strong relationship between HCV infection and impaired physical health\(^{[111]}\), as well as an inverse correlation between levels of brain-derived neurotrophic factor and physical health, has been documented in patients with HCV but not in those with HBV infection\(^{[112]}\).

The most frequent psychiatric symptom reported in chronic HCV infection is fatigue\(^{[100]}\), mainly manifesting as physical and mental exhaustion, often in association with attention deficit and word-finding difficulty, depression, headache, osteoarticular pain, and sleep disturbances. Although insomnia has been reported in up to 60% of cases, it can also be dependent on other psychiatric comorbidities, such as depression, or on such medical conditions as anemia and hypothyroidism\(^{[113]}\), frequently associated with chronic HCV infection. Old age, female gender, and single status have been found to be predictive of fatigue in HCV patients\(^{[111,114]}\). Metabolic and neurotransmitter alterations in the ascending reticular activating system, limbic system, globus pallidus, and putamen have been hypothesized to play a role in the development of chronic fatigue syndrome\(^{[11]}\).

Depression and/or anxiety have been reported in about one third of HCV-infected patients; brief, recurrent episodes of depression or anxiety have been recorded in nearly 15% of patients\(^{[115]}\). Navinés et al\(^{[116]}\) reported an 18.2% overall prevalence of depressive disorders, as diagnosed according to DSM-IV criteria, in a series of 500 HCV-positive patients. Specifically, major depressive disorder, generalized anxiety, and panic were present in 6.4%, 7.0%, and 5.8% of the patients, respectively.

One report suggested that HCV genotype 3 infected patients might be at increased risk of depression\(^{[111]}\). However, it should be remembered that such patients are often drug users, which itself puts them at risk of depression. Moreover, depression was independently associated with perceived barriers to accessing HCV care, thus creating a vicious circle\(^{[117]}\).

### HCV infection and pathogenic mechanisms of neurotoxicity

Several mechanisms have been proposed to explain the pathogenesis of neuropsychiatric disorders observed in chronic HCV infection.

### HCV and direct neuroinvasion

Although HCV is primarily a hepatotropic virus, HCV RNA has also been detected in peripheral mononuclear blood cells\(^{[118]}\) and in the brain of chronically infected patients with neuropathologic abnormalities. Evidence of HCV neuroinvasion is now accumulating\(^{[15,119,120]}\). Seifert et al\(^{[80]}\) found the viral genome in the brain tissue of a young woman with encephalitis; likewise, Vargas et al\(^{[121]}\) identified HCV RNA negative strands, i.e., viral replicative forms, in the subcortical white matter and cerebral cortex from two patients. Similarly, Wilkinson et al\(^{[122]}\) detected HCV RNA in CD68-positive cells of CNS (macrophages/microglia) from 8 patients; HCV RNA negative strands were found in three patients. Microglial cells, a resident CNS macrophage population, have been hypothesized to be the main targets for HCV entry into the CNS\(^{[123]}\). Specifically, macrophages may warrant virus access into the CNS through a ‘Trojan horse’ mechanism, in a process similar to that hypothesized for HIV. CNS infection may follow HCV virus replication in peripheral blood mononuclear cells, which are able to cross the blood brain barrier and to serve as precursors of CNS microglial cells\(^{[17,122,124]}\). Moreover, tumor necrosis factor-α (TNF-α) and interleukin 8 (IL-8), which are associated with neuropsychiatric disorders, have been found to be secreted by HCV-infected...
microglial cells. A close relationship between HCV RNA sequences detected in the brain and cerebrospinal fluid and those found in lymph nodes and peripheral blood mononuclear cells comes in support of this hypothesis. Conversely, the diversity of viral quasispecies between the CNS and liver supports the notion of independent viral evolution in the two sites of replication. Evidence suggests that brain-specific viral variants may favor HCV latency in the CNS, possibly because of mutations in the viral gene IRES, which is known to drive the initial translocation of viral polyproteins.

Since HCV core and non-structural NS3 and NS5A proteins have been found to activate macrophages/microglia as well as astrocytes of infected patients, HCV proteins have been hypothesized to have a role in inducing neurotoxicity. HCV core protein has been described to mediate neuronal injury by suppression of neuronal autophagy and through immune activation. Specifically, HCV core protein has been demonstrated to activate both toll-like receptor 2 (TLR2) signaling and extracellular signal-related kinase (ERK); neurotoxicity has been described to result from prolonged TLR2-mediated activation of ERK.

Brain microvascular endothelial cells have been recently demonstrated to support HCV tropism and replication. HCV has been shown to induce apoptosis in these cells, leading to changes in the permeability of the blood brain barrier, microglia activation, and diffusion of pro-inflammatory cytokines into the CNS.

However, evidence for an association between HCV neuroinvasion and neuropsychiatric disorders is currently scarce; indeed, replication of quasispecies occurs at a very low level within the CNS and HCV RNA is almost undetectable in cerebrospinal fluid; finally, a poor correlation between viral load and clinical manifestations has been reported.

**HCV and changes in metabolic pathways**

On proton magnetic resonance spectroscopy, metabolic abnormalities of choline/creatinine ratio in basal ganglia and white matter have been detected in patients with histologically proven mild hepatitis C with respect to both healthy volunteers and chronic hepatitis B patients, suggesting a role for HCV itself in affecting cerebral functions. Moreover, significant correlations have been reported between cognitive dysfunction and HCV replication and between degree of impairment and the choline/creatinine ratio in the basal ganglia and white matter; in contrast to what is commonly observed in hepatic encephalopathy, a higher content in cerebral choline has been recorded in these patients. Although the exact significance of elevated choline in the white matter remains uncertain, it may be implicated in glial activation secondary to oxidative stress; a similar mechanism has been suggested for chronic fatigue syndrome in HIV infection.

N-acetyl aspartate (NAA) is considered to be a marker of functional integrity of nervous cells and pathways; low levels are indeed associated with memory deficiency. Weissenborn et al. showed a significantly decreased NAA/creatinine ratio in the cerebral cortex, but not changes in the choline/creatinine ratio, in chronic HCV infected patients with cognitive impairment, anxiety, and depression, with respect to healthy controls; EEG was slowed in 25% of cases. In a study involving 53 HCV-positive patients with neuropsychiatric symptoms, Bokemeyer et al. found increased choline and myo-inositol levels in basal ganglia and white matter as well as altered concentrations of creatine and NAA in basal ganglia, indicative of glial activation and macrophage infiltration. These findings were in support of HCV-induced neuro-inflammation and brain dysfunction.

Changes in neurotransmission have also been hypothesized in HCV infected patients with psychiatric disorders. In this context, Weissenborn et al. reported increased anxiety and depression in parallel with changes in both the midbrain serotoninergic and striatal dopaminergic systems, irrespective of HCV viremia and liver disease severity. Ondansetron, a competitive antagonist of serotonin receptors, has been shown to be effective in reducing HCV-related fatigue and depression, thus corroborating the suggestion of serotonergic pathway dysfunction. Moreover, decreased serum tryptophan levels and serotonin synthesis has been documented in HCV patients. However, since ondansetron treatment has been associated with clinical benefit in only a third of cases, additional factors are probably involved in HCV-related cognitive impairment. Heeren et al. reported reduced brain dopamine availability in 15 HCV-positive patients with neuropsychiatric symptoms, thus underscoring the prominent role of defective dopaminergic transmission in determining cognitive impairment in HCV patients.

**HCV and cerebral and systemic inflammation**

As discussed above, chronic HCV infection is associated with systemic and local inflammation that may play a role in the pathogenesis of neuropsychiatric disorders as well. Huckans et al. identified a proinflammatory profile in HCV-positive patients, significantly correlated with neuropsychiatric symptoms. In HCV infected patients, a local inflammatory response mediated by IL-8 and TNF-α derived from HCV-infected brain macrophages/microglia has been described. Chronic activation of the immune system results in the production of such cytokines as IL-1, IL-6, IL-4, and TNF-α, which are responsible for the neuronal changes underlying neurological impairments. Peripheral proinflammatory cytokines, like IL-1 and IL-6, can interfere with neurotransmitter systems thus predisposing to neuropsychiatric disorders; indeed, increased levels of IL-6 have been reported to be associated with impairment of memory and spatial
learning in chronic HCV infection\cite{140-142}; moreover, an inverse correlation between plasma levels of IL-6 and both cognitive performance and executive function has been described\cite{143}.

In summary, despite a consistent number of studies, the pathogenic mechanisms of HCV-induced neurotoxicity remain still unclear. A complex interaction among different HCV-driven derangements may be hypothesized to contribute to neurologic impairment. Further studies are ongoing and will hopefully shed light on the complex mechanisms of interaction between HCV and the nervous system. Recently, even the endocannabinoid system has been suggested to play a role in liver disease. Specifically, CB1 seems to be upregulated in patients with chronic hepatitis C\cite{144}, while CB1 receptor has been found in high concentrations in the brain. Coppola et al\cite{145} demonstrated an association between a genetic polymorphism, i.e., CB2-63 QQ variant, and more severe hepatic inflammation in HCV-positive patients, supporting a role for CB2 receptor in HCV-associated inflammation and cellular proliferation. Thus, the role of the endocannabinoid system in HCV-related neuropsychiatric disorders deserves further investigations, particularly in light of the possibility of being therapeutically targeted\cite{12}.

Impact of HCV treatment on neuropsychiatric disorders: Present and perspectives

Standard of care for HCV treatment is based on a regimen including pegylated interferon plus ribavirin. An improvement in response rates has been obtained with addition of viral protease inhibitors, namely, boceprevir and telaprevir, to standard of care; recently, new oral drugs, sofosbuvir and simeprevir, have been approved for use. These drugs warrant even higher response rates and can also be used without interferon. Obviously, data are lacking on the impact of these new drugs on neuropsychiatric disorders in chronic hepatitis C patients, whereas evidence is available with regard to the effects of interferon-based therapy.

While interferon-α treatment itself is known to possibly determine neuropsychiatric side effects, on the other hand, the drug ability to improve neurological and psychiatric symptoms in HCV patients achieving a sustained virologic response (SVR) has been frequently reported in the literature\cite{146}. In particular, subjects obtaining a SVR experienced an improvement in quality of life independently of liver disease severity\cite{105,146-149}. Moreover, SVR has also been associated with improvement in cognitive function\cite{150}, irrespective of outcome of quality of life. Vitality, social and work functioning, productivity, health distress, HCV-specific distress, and fatigue all have been recorded to ameliorate following response to interferon therapy\cite{192}. However, caution should be exercised when considering the conclusions of these studies, since patient satisfaction due to awareness of being healed from hepatitis C may potentially bias interpretation of study results\cite{190}. Recently, patients achieving a SVR have been shown to display reduced brain inflammation and improved neuropsychological functions, including verbal learning, memory, and visual–spatial memory, when compared to interferon nonresponders\cite{151}; moreover, significantly reduced choline/creatine and myo-inositol/creatine ratios have been detected in the basal ganglia of SVR patients, in contrast to nonresponders or relapsing patients.

Importantly, obtaining a SVR following interferon treatment has been reported to even reduce the risk of stroke in chronic HCV infected patients. Specifically, Hsu et al\cite{140} calculated a 61% reduction in the long-term stroke risk after adjusting for known prognostic factors.

Overall, the studies performed thus far, albeit with limitations due to the small number of patients, seem to indicate a beneficial effect of interferon-induced SVR on both neurological and psychiatric disorders; however, further ad hoc trials are needed to confirm these results.

Since HCV-related cryoglobulinemia has been associated with impaired neurological and cognitive functions, treatment of cryoglobulinemia should theoretically lead to improvement of neuropsychiatric symptoms. The standard of care for HCV-related mixed cryoglobulinemia is based on the association pegylated interferon plus ribavirin\cite{152}. In HCV cryoglobulinemic patients, a gradual improvement in neurological symptoms has been observed after plasmapheresis and immunosuppressant therapy\cite{153}.

CONCLUSION

At the end of this overview, some considerations are due. Interpretation of study results should be done with a note of caution, because of the non-confirmatory nature of some reports, the structure of the studies, and the criteria used for study inclusion. Case-control and longitudinal studies relying on neurocognitive tests, quality-of-life questionnaires, and/or magnetic resonance spectroscopy imaging have been carried out to investigate HCV-related neuropsychiatric features. Several issues may be questioned, including the characteristics of HCV-negative controls used for comparisons and the heterogeneity of HCV-positive populations enrolled in the studies, due to coexistence of potentially confounding factors, namely, comorbidities, addictive behavior, and different stages of liver disease, particularly presence of cirrhosis. All these factors have not always been taken into due consideration. Despite these limitations, HCV seems to play an important role in the development of both cerebrovascular events and peripheral neuropathy. In addition, a
higher prevalence of fatigue, depression, and cognitive impairment has also been reported. However, the majority of HCV-associated neuropsychiatric disorders are mild and not generalizable to the whole HCV population. Indeed, a significant number of infected patients are highly fruitful individuals; besides, neuropsychiatric symptoms are potentially reversible following therapeutic HCV clearance. Further studies are necessary for a better elucidation of the role played by HCV in neuropsychiatric disorders and to specifically institute effective treatments. At present, in the diagnostic work-up of a patient with the above reported neuropsychiatric disorders, clinicians should also consider to screen for HCV infection.

REFERENCES

1 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]

2 Zigone AR, Crazzi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12: 611-36, ix [PMID: 18625431 DOI: 10.1016/j.cld.2008.03.012]

3 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011; 12: 2215-2234 [PMID: 21888305 DOI: 10.1517/14656566.2011.597742]

4 Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerra B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410-3417 [PMID: 24707124 DOI: 10.3748/wjg.v20.i13.3410]

5 Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero G, Adinolfi LE. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004; 38: 901-905 [PMID: 15492610]

6 Johnson RJ, Gretch DR, Yamabe H, Hart J, Baccei CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470 [PMID: 7678440]

7 Antonelli A, Ferri C, Pumpana P, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-13 [PMID: 15210382]

8 Féra C. Is hepatitis C a neurologic disorder? Gastroenterology 2012; 142: 428-431 [PMID: 22885362 DOI: 10.1053/j.gastro.2012.01.010]

9 Adinolfi LE, Utili R, Attanasio V, Zampino R, Ragone E, Tripodi A, Ruggiero G. Epiclinical, epidemiologic, clinical spectrum and prognostic value of mixed cryoglobulinemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol 1996; 28: 1-9 [PMID: 8743066]

10 Nagao Y, Sata M. Hepatitis C virus and liver chen planus. J Gastroenterol Hepatol 2004; 19: 1101-1113 [PMID: 15377286 DOI: 10.1046/j.1440-1746.2003.03324.x]

11 Revie D, Salahuddin ZZ. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virology 2011; 8: 346 [PMID: 21745397 DOI: 10.1186/1743-422X-8-346]

12 Zampino R, Marrone A, Restivo L, Guerra B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5: 528-540 [PMID: 24179612 DOI: 10.4245/wjh.v5.i10.528]

13 Monaco S, Ferrari S, Gajofatto A, Zanussi G, Mariotti S. HCV-related nervous system disorders. Clin Dev Immunol 2012; 2012: 236148 [PMID: 22899946 DOI: 10.1155/2012/236148]

14 Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 1998; 315: 208-210 [PMID: 9519936]

15 Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat 2012; 19: 301-306 [PMID: 22497808 DOI: 10.1111/j.1365-2893.2012.01951.x]

16 Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela J, Laskus T. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Viral 2002; 76: 600-608 [PMID: 11752151]

17 Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78: 5170-5183 [PMID: 15113899]

18 Adinolfi LE, Restivo L, Guerra B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis 2013; 231: 22-26 [PMID: 21425405 DOI: 10.1016/j.atherosclerosis.2013.08.003]

19 Petty GW, Duffy J, Houston J. Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Mayo Clin Proc 1996; 71: 671-678 [PMID: 8657090]

20 Cacoub P, Shai A, Hausfather P, Papo T, Gatel A, Piette JC. [Central nervous system involvement in hepatitis C virus infection]. Gastroenterol Clin Biol 1998; 22: 631-633 [PMID: 9762334]

21 Egerer C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014; 31: 891-903 [PMID: 25047758 DOI: 10.1007/s12325-014-0138-4]

22 Gutierrez J, Elikind MS. Chronic inflammatory diseases and stroke: Evidence for heterogeneous mechanisms. Ann Neurol 2012; 72: S6-S7

23 Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012; 7: e31527 [PMID: 22363662 DOI: 10.1371/journal.pone.0031527]

24 Hsu CS, Kao JH, Chao YC, Lin YH, Fan YC, Huang CJ, Tsai PS. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-423 [PMID: 23802888 DOI: 10.1111/apt.12391]

25 Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013; 37: 647-652 [PMID: 23384408 DOI: 10.1111/apt.12234]

26 He Huang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS One 2013; 8: e81305 [PMID: 24265844 DOI: 10.1371/journal.pone.0081305]

27 Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, Chen CJ. Hepatitis C virus infection and mixed cryoglobulinemia. Atherosclerosis 2010; 219: 1923-1932 [PMID: 20966408 DOI: 10.1111/j.1600-0314.2010.059136]

28 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143 [PMID: 11877368]

29 Stoll G, Bendzus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-1923 [PMID: 16741184]

30 Adinolfi LE, Restivo L, Zampino R, Guerra B, Lonardo A, Ruggiero L, Rielo F, Loria P, Florio A. Chronic HCV infection is a risk of cerebrovascular disease. Stroke 2010; 41: 2894-2900 [PMID: 20966408 DOI: 10.1161/STROKEAHA.110.598136]

31 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease.
Adinolfi LE et al. HCV and neuropsychiatric diseases

Gastroenterology 2012; 142: 634-643.e6 [PMID: 22138189 DOI: 10.1053/j.gastro.2011.11.028]

Seifert F, Struifff T, Hildebrandt M, Blümcke I, Brück W, Staykov D, Huttner HB, Hilz MJ, Schwab S, Bardutzky J. In vivo detection of hepatitis C virus (HCV) RNA in the brain in a case of encephalitis: evidence for HCV neuroinvasion. Eur J Neurology 2008; 15: 214-218 [PMID: 18215154 DOI: 10.1111/j.1468-1331.2007.02044.x]

Bolay H, Söylemezoglu F, Nurlu G, Tuncer S, Varli K. PCR detected hepatitis C virus genome in the brain of a case with progressive encephalomyelitis with rigidity. Clin Neurol Neurosurg 1996; 98: 305-308 [PMID: 9087176]

Grewal AK, Lopes MB, Berg CL, Bennett AK, Alves VA, Trugman JM. Recurrent demyelinating myelitis associated with hepatitis C virus infection. J Neurol Sci 2004; 224: 101-106 [PMID: 15450779]

Zandman-Goddard G, Levy Y, Weiss P, Shoenfeld Y, Langevitz P. Transverse myelitis associated with chronic hepatitis C. Clin Exp Rheumatol 2003; 21: 111-113 [PMID: 12677901]

De Carli DM, Pannebecker J, Pedro FL, Haygert CJ, Hertz E, Beck Mde O. Transverse myelitis associated to HCV infection. Braz J Infect Dis 2009; 13: 147-152 [PMID: 21043631]

Aktili KM, Raviglia S, Ceroni M, Nenni R, Debiaggi M, Bastianello S, Alfonsi E, Zardini E, Minoli L, Tavazzi E, Marchioni E. Severe recurrent myelitis in patients with hepatitis C virus infection. Neurology 2007; 68: 468-469 [PMID: 17283325]

Sacconi S, Salvati L, Merelli E. Acute disseminated encephalomyelitis associated with hepatitis C virus infection. Arch Neurol 2001; 58: 1679-1681 [PMID: 11594929]

Sim JE, Lee JB, Cho YN, Sub SH, Kim JK, Lee KY. A case of acute disseminated encephalomyelitis associated with hepatitis C virus infection. J Neurol Sci 2012; 53: 856-858 [PMID: 22665357 DOI: 10.3349/jnn.2012.53.4.856]

Forton DM, Thomas KA, Murphy CA, Allsop JM, Foster GR, Main J, Wenkes KA, Taylor-Robinson SD. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-439 [PMID: 11826420]

Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440-446 [PMID: 11826421]

Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847-854 [PMID: 14632243]

Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steinfl-Munda P, Wiba F, Madli C, Gangl A, Ferenc P. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 37: 349-354 [PMID: 12175630]

Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfloh Z, Lok AS, Fontana RJ. Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc 2007; 13: 687-692 [PMID: 17521478]

Cichern M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 1343-1347 [PMID: 15851720]

McAndrews MP, Farenc K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-808 [PMID: 15793853 DOI: 10.1002/hep.20635]

Córdoba J, Flaviet M, Jacobs C, Saudela S, Esteban JL, Vargas V, Esteban R, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231-238 [PMID: 12873820]

Martin EM, Novak RM, Fendrich M, Vassileva J, Gonzalez R, Grbesic S, Nunnally G, Sworowski L. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc 2004; 10: 298-300 [PMID: 15012850]

Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL,
2001; 79: 47-56 [PMID: 10670409]

Zaltron S, Puoti M, Liberini P, Antonini L, Quattrini A, Santuccio G, Camerlingo M, Hurowitz B, Hassan N, Du VT, Nadir A. Complex pathogenesis of cryoglobulinemic neuropathy. J Neurol Neurosurg Psychiatry 2001; 73: 354-355 [PMID: 10948890]

Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musslet L, Veyssier P, Rugain G, Piette JC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMMIVC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 2000; 79: 47-56 [PMID: 10670409]

Migliaresi S, Di Iorio G, Ammadella A, Ambrosone L, Sanges G, Ugolini G, Sampaolesi S, Bravaccio F, Tirri G. [Peripheral nervous system involvement in HCV-related mixed cryoglobulinaemia] Reumatismo 2001; 53: 26-32 [PMID: 12461575]

Vital C, Vital A, Canron MH, Jaffre A, Viallard JF, Ragnaud JM, Brechmacher C, Laguena A. Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst 2006; 11: 20-29 [PMID: 16519779]

Gemignani F, Melli G, Inglese C, Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst 2002; 7: 59-64 [PMID: 11939353]

Gemignani F, Brindani F, Alfieri S, Giuberti T, Allegrè I, Ferrari C, Marbini A. Clinical spectrum of cryoglobulinemic neuropathy. J Neurol Neurosurg Psychiatry 2005; 76: 1410-1414 [PMID: 16100807]

Herrmann DN, Ferguson ML, Pannoni V, Barbano RL, Stanton M, Logigian EL. Plantar nerve AP and skin biopsy in sensory neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst 2004; 9: 62-63 [PMID: 15353266]

Gemignani F, Marbini A. Restless legs syndrome and peripheral neuropathy. J Neurol Neurosurg Psychiatry 2002; 72: 555 [PMID: 11900992]

Temb J, Ferrer JM, Sevilla MT, Lago A, Mayordomo F, Vileche JJ. Neurologic complications associated with hepatitis C virus infection. Neurology 1999; 53: 861-864 [PMID: 10489556]

Bant A, Hurwitz B, Hassan N, Du VT, Nadir A. Complex regional pain syndrome (reflex sympathetic dystrophy) in a patient with essential mixed cryoglobulinemia and chronic hepatitis C. J Pak Med Assoc 2007; 57: 96-98 [PMID: 17370795]

Nemni R, Corbo M, Fazio R, Quattrini A, Comi G, Canal N. Cryoglobulinemic neuropathy. A clinical, morphological and immunocytological study of 8 cases. Brain 1988; 111 (Pt 3): 541-552 [PMID: 2838123]

Chad D, Pariser K, Bradley WG, Adelman LS, Finn PW. The pathogenesis of cryoglobulinemic neuropathy. Neurology 1982; 32: 725-729 [PMID: 6283424]

Wyck PJ, Benstead TJ, Conn DL, Stevens JC, Windebank AJ, Low PA. Nonsystemic vasculitic neuropathy. Brain 1987; 110 (Pt 4): 843-853 [PMID: 3651797]

Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M, Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinemia. J Neurol Neurosurg Psychiatry 2003; 74: 1267-1271 [PMID: 12933932]

Bonetti B, Invernizzi F, Rizzuto N, Bonazzi ML, Zanuso GL, Chinaglia G, Monaco S. T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy. J Neuromuscul Dis 1997; 7: 145-154 [PMID: 9058770]

Aurthier EF, Bassay G, Payan C, Guillelmin L, Pawlotsky JM, Degos JD, Ghendarik RD, Belec L. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 2003; 60: 808-812 [PMID: 12629238]

Younis LK, Talata FM, Deif AH, Borei MF, Reheim SM, El Salmawy DH. Immunohistochemical detection of HCV in nerves and muscles of patients with HCV associated peripheral neuropathy and myositis. Int J Health Sci (Qassim) 2007, 1: 195-202 [PMID: 21475426]

Paoletti V, Donnarumma L, De Matteis A, Mammarella A, Labbadia G, Musca A, Francia A. Peripheral neuropathy without cryoglobulinemia in patients with hepatitis C virus infection. Panminerva Med 2000; 42: 175-176 [PMID: 11218620]

Lidove O, Cacoub P, Maisonneuve T, Servan J, Thibault V, Piette JC, Leger JM. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinemia. Ann Rheum Dis 2001; 60: 290-292 [PMID: 11171666]

Bonetti B, Monaco S, Giannini C, Ferrari S, Zanuso G, Rizzuto N. Human peripheral nerve macrophages in normal and pathological conditions. J Neurol Sci 1993; 118: 158-168 [PMID: 8229064]

De Martino L, Sampaolo S, Tucci C, Ambrosone L, Budillon A, Migliaresi S, Di Iorio G. Viral RNA in nerve tissue of patients with hepatitis C infection and peripheral neuropathy. Muscle Nerve 2003; 27: 102-104 [PMID: 12508302]

Gemignani F, Pavesi G, Fiocchi A, Manganelli P, Ferraccioli G, Marbini A. Peripheral neuropathy in essential mixed cryoglobulinemia. J Neurol Neurosurg Psychiatry 1992; 55: 116-120 [PMID: 1311372]

Costa J, Resende C, de Carvalho M. Motor-axonal polyneuropathy associated with hepatitis C virus. Eur J Neurol 2003; 10: 183-185 [PMID: 12603295]

Ammendola A, Sampaolo S, Migliaresi S, Ambrosone L, Ammadella E, Ciccone G, Di Iorio G. Autonomic neuropathy in mixed cryoglobulinemia. J Neurol 2007; 254: 215-219 [PMID: 17334955]

Lippa CF, Chad DA, Smith TW, Kaplan MH, Hammer K. Hepatitis B virus involvement in HCV-related mixed cryoglobulinemia. J Gastroenterol Hepatol 2000; 15: 1026-1030 [PMID: 11171666]

Boukhris S, Magy L, Senga-mokono U, Loustaud-ratti V, Vallat JM. Polyneuropathy with demyelinating features in mixed cryoglobulinemia with hepatitis C virus infection. J Gastroenterol Hepatol 2006; 21 (Pt 3): 937-941 [PMID: 16930357]

Bezerra ML, Harumi JA, Shinosaki JS, Pedroso JL, Henriques de Aquino CC, de Souza LT, Baiense RF, Bulle de Oliveira AS. Hepatitis C virus: a rare manifestation--remitting relapsing central nervous system involvement in HCV-related mixed cryoglobulinemia. J Neurol Neurosurg Psychiatry 2006; 77: 145-154 [PMID: 90514113]

Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212 [PMID: 9425939]

Amadio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, Minazzato L. Hepatitis C virus infection and health-related quality of life. World J Gastroenterol 2012; 18: 2295-2299 [PMID: 22654420 DOI: 10.3748/wjg.v18.i19.2295]

Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer
In vivo magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. 
Prostaglandins Leukot Essent Fatty Acids 2004; 71: 181-183 [PMID: 15253888]
Adinolfi LE et al. HCV and neuropsychiatric diseases

137 Cozzi A, zigngeo AL, Carpendo R, biaggiotti T, Aldinucci A, Monti M, Gianmini C, Rosselli M, Laffi G, Moroni F. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. *J Viral Hepat* 2006; 13: 402-408 [PMID: 16842443]

138 weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H, Trebst C, Hecker H, Berding G. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. *Gut* 2006; 55: 1624-1630 [PMID: 16682431]

139 Heeren M, weissenborn K, Arvanitis D, Bokemeyer M, Goldbecker A, Tountopoulou A, Peschel T, Grosskreutz J, Hecker H, Buchtet R, Berding G. Cerebral glucose utilisation in hepatitis C virus infection-associated encephalopathy. *J Cereb Blood Flow Metab* 2011; 31: 2199-2208 [PMID: 21629258 DOI: 10.1038/jcbfm.2011.82]

140 Hucks M, Fuller BE, Olavarria H, Sasaki AW, Chang M, Flora KD, Kolessar M, Krij D, Anderson JR, Vandenbark AA, Lofts JM. Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection. *Brain Behav* 2014; 4: 123-142 [PMID: 24683507 DOI: 10.1002/brb3.200]

141 Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. *Biol Psychiatry* 2004; 56: 819-824 [PMID: 15576057]

142 Capuron L, Pagnoni G, Demetrashvili M, Woolwine BJ, Neeromon CB, Bens BS, Miller AH. Anterior cingulate activation and error processing during interferon-alpha treatment. *Biol Psychiatry* 2005; 58: 190-196 [PMID: 16084839]

143 Marsland AL, Petersen KL, Sathanorri R, Muldoon MF, Neumann SA, Ryan C, Flory JD, Manuck SB. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. *Psychosom Med* 2006; 68: 895-903 [PMID: 17132839]

144 van der Poorten D, Shahidi M, Tay E, Sesha J, Tran K, McLeod D, Miliken JS, Ho V, Hebbard LW, Douglas MW, George J. Hepatitis C virus induces the cannabinoid receptor 1. *PLoS One* 2010; 5: [PMID: 20882263 DOI: 10.1371/journal.pone.0012841]

145 Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Miraglia Del Giudice E, Rossi F. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. *Clin Gastroenterol Hepatol* 2014; 12: 334-340 [PMID: 23707465 DOI: 10.1016/j.cgh.2013.05.008]

146 Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. *Hepatology* 2005; 41: 790-800 [PMID: 15791608]

147 Foster GR. Quality of life considerations for patients with chronic hepatitis C. *J Viral Hepat* 2009; 16: 605-611 [PMID: 19674284 DOI: 10.1111/j.1365-2893.2009.01154.x]

148 Bernstein D, Kleiman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. *Hepatology* 2002; 35: 704-708 [PMID: 11870387]

149 Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virapeh-C study. *J Hepatol* 2012; 57: 946-952 [PMID: 22760009 DOI: 10.1016/j.jhep.2012.06.030]

150 Thein HH, Maruff P, Krahn MJ, Kaldor JM, Kookey DJ, Brew BJ, Dore GJ. Improved cognitive function as a consequence of hepatitis C virus treatment. *HIV Med* 2007; 8: 520-528 [PMID: 17944685]

151 Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alspong D, Lenkinski R, Aldhahel NH. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. *J Hepatol* 2012; 56: 549-556 [PMID: 22027578 DOI: 10.1016/j.jhep.2011.09.015]

152 Adinolfi LE, Ugli R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. *Eur J Gastroenterol Hepatol* 1997; 9: 1067-1072 [PMID: 9431896]

153 Bucoliero R, Gambelli S, Sicurelli F, Malandrini A, Palmieri S, De Santis M, Stromillo ML, De Stefano N, Sperduto A, Musumeci SA, Federico A. Leukoencephalopathy as a rare complication of hepatitis C infection. *J Cereb Blood Flow Metab* 2011; 31: 2199-2208 [PMID: 21629258 DOI: 10.1038/jcbfm.2011.82]

154 Kralik J, Martinovski P, Cabral MF, Kahlert P, Breyer V, Scholzker J, Zinn L, Holzinger A, Zinserling J, Rane A. Effect of long-term course of alpha-interferon on cerebral metabolism and cognition. *J Hepatol* 2012; 56: 549-556 [PMID: 22027578 DOI: 10.1016/j.jhep.2011.09.015]

155 Adinolfi LE, Ugli R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. *Eur J Gastroenterol Hepatol* 1997; 9: 1067-1072 [PMID: 9431896]

156 Bucoliero R, Gambelli S, Sicurelli F, Malandrini A, Palmieri S, De Santis M, Stromillo ML, De Stefano N, Sperduto A, Musumeci SA, Federico A. Leukoencephalopathy as a rare complication of hepatitis C infection. *Neurol Sci* 2006; 27: 360-363 [PMID: 17122948]

P- Reviewer: Kim SR, Pazienza V S- Editor: Ma YJ L- Editor: A E- Editor: Zhang DN
Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window

Vincenzo La Mura, Giulia Tosetti, Massimo Primignani, Francesco Salerno

Abstract

Non selective beta blockers (NSBBs) are used in primary and secondary prophylaxis of portal hypertension-related bleeding in patients with cirrhosis. The efficacy of NSBBs treatment is predicted by hemodynamic response in term of reduction of the hepatic venous pressure gradient (HVPG) below 12 mmHg or at least 20% of the basal value. Nevertheless a relevant number of patients who do not achieve this HVPG reduction during NSBBs therapy do not bleed during follow up; this evidence suggests an additional non-hemodynamic advantage of NSBBs treatment to modify the natural history of cirrhosis. Recent studies have questioned the efficacy and safety of NSBBs in patients with advanced stage of liver disease characterized by refractory ascites and/or spontaneous bacterial peritonitis. These studies have suggested the existence of a defined and limited period to modify the natural history of cirrhosis by NSBBs: the “window hypothesis”. According with this hypothesis, patients with cirrhosis benefit from the use of NSBBs from the appearance of varices up to the development of an advanced stage of cirrhosis. Indeed, in patients with refractory ascites and/or spontaneous bacterial peritonitis the hemodynamic effects of NSBBs may expose to a high risk of further complications such as renal insufficiency and/or death. Methodological concerns and contrasting results counterbalance the evidence produced up to now on this issue and are the main topic of this editorial.

Key words: Bleeding prophylaxis; End stage liver disease; Non-selective beta blockers; Portal hypertension; Cirrhosis

Core tip: Non selective beta blockers (NSBBs) treatment in cirrhotic patients is an undisputed strategy for bleeding prophylaxis. Nevertheless recent studies question the efficacy and safety of NSBBs in patient with advanced cirrhosis, particularly in case of refractory ascites and spontaneous bacterial peritonitis. These results suggest that NSBBs have beneficial effects on cirrhosis only in a determinate phase of the liver disease: “window hypothesis”. In our opinion, the evidence produced up to now is by far conclusive to contraindicate NSBBs in patients with advanced cirrhosis.
La Mura V et al. Debate on the window hypothesis

La Mura V, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window. World J Gastroenterol 2015; 21(8): 2265-2268 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i8/2265.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i8.2265

INTRODUCTION

Since their introduction to reduce the re-bleeding risk in-patients with cirrhosis[1], the therapy with non-selective beta blockers (NSBBs) has been widely tested to successfully manage the risk of complications of portal hypertension (PHT) ranging from the first evidence of varices up to the bleeding related mortality[2-5]. Moreover, therapy with NSBBs has been tested to prevent other complications such as the de novo appearance of spontaneous bacterial peritonitis (SBP), hepato-renal syndrome (HRS), and hepatic encephalopathy[2-6].

The hepatic venous pressure gradient (HVPG), the difference between the wedge and the free hepatic venous pressure, measured by hepatic vein catheterization, is one of the most reliable surrogate markers of clinical outcome in patients with chronic liver disease[7]. A HVPG ≥ 10mmHg is independently associated with the appearance of esophageal varices and/or ascites in patients with cirrhosis, whereas a HVPG ≥ 12mmHg is the threshold for the risk of variceal rupture and bleeding[8]. Recently, investigators of PHT proposed a functional classification of cirrhosis according to a progressive multistage mortality risk[9,10]. In line with this patient stratification, the one-year mortality after a variceal bleeding episode is 40%. This risk can be reduced by the chronic treatment with NSBBs[11] mainly in patients achieving a significant reduction of HVPG[2,3].

The therapy with NSBBs was based on the recognition that a hyperkinetic circulation is behind the development of symptoms of PHT. This circulatory state is maintained by a persistent vasodilation of the splanchnic arterial bed with reduction of the central blood volume, increased heart rate and cardiac output, and retention of sodium and fluids by the kidney[12]. The reduction of this hyperkinetic circulation is the main target of therapy with NSBBs for cirrhotic patients. Indeed, the blockade of beta-1 receptors antagonizes the high cardiac output, whereas the blockade of beta-2 receptors allows the alpha-adrenergic tone to blunt the splanchnic arterial vasodilation with a lowering effect on portal pressure. Therefore, these pharmacodynamic effects can prevent a rupture of varices. A reduction of the HVPG below 12 mmHg or at least 20% of its basal value (hemodynamic response) under NSBBs is a highly specific predictor of protection from variceal rupture (good clinical response). Conversely, patients who do not achieve this HVPG reduction despite NSBBs therapy (hemodynamic non-responders) are at the highest risk of variceal rupture, although up to 48% of them does not bleed during a relatively large period of time[13]. This unexpected behavior could be explained assuming that these non-bleeding patients are protected by NSBB therapy even if they do not obtain the sufficient reduction of portal pressure. A few of other hemodynamic and non-hemodynamic effects of NSBB have been evoked to justify this clinical advantage[13]. Among them, the ability of NSBBs to reduce the gastro-intestinal permeability to bacterial by-products is a favorable effect that occurs in both hemodynamic responders and non-responders[14]. This is a crucial issue because the ability to cross intestinal barrier by bacteria and by bacterial by-products [bacterial translocation (BT)] is the main risk factor for the SBP, that in turn is the main trigger of HRS.

The efficacy of NSBBs in preventing SBP has been shown by Turnes et al[15] who demonstrated that a partial reduction of HVPG (11% instead of 20%) during NSBB therapy was enough to reduce the risk of SBP for a long period of time; while the meta-analysis made by Senzolo et al[16] including data from 5 studies, confirmed that the treatment with NSBBs reduces the risk of SBP.

Recently the French group who demonstrated, for the first time, the efficacy of NSBBs therapy to prevent variceal rupture, published a retrospective cohort study of 151 patients with refractory ascites finding that the treatment with NSBBs was independently associated with mortality [hazard ratio (HR) = 2.61 times, 95%CI: 1.91-3.44][16]. A similar concern for the safety of patients was raised for the risk of developing post-paracentesis circulatory dysfunction (PPCD) after large volume paracentesis[17]. In addition, Mandorfer et al[18] reported the outcome of 182 incidental cases of SBP where the chronic treatment with NSBBs (n = 86) had exposed to an elevated cumulative risk of renal failure, either defined with the criteria of HRS (11% vs 24%, respectively) either defined as acute kidney injury, AKI (8% vs 20%, respectively).

All these observations fostered the hypothesis that patients with cirrhosis and PHT may take advantage from the therapy with NSBBs only if they fall in a well-defined window of the natural story of the disease. This window would be opened by the first appearance of esophageal varices at risk of bleeding and would be closed by the development of refractory ascites or other severe complications like SBP/HRS that are clinical hallmarks of an advanced liver disease[19].

The observation by Ruiz-del-Arbol et al[20] that patients with SBP develop renal failure in association with reduction of cardiac output and mean arterial pressure can explain why NSBB therapy would be detrimental for survival of patients with advanced cirrhosis. This study and other similar evidences induced authors to revise the “theory of peripheral vasodilation” adding to the well-known algorithm a final
stage including patients characterized by a hyperkinetic circulation that slows down as a consequence of a relative failure of cardiac output\[23\]. Accordingly, the inotropic and hypotensive effects of NSBBs could represent a danger for patients with advanced cirrhosis and refractory ascites and/or HRS. By contrast, many other investigators continue to prescribe NSBBs to patients with advanced cirrhosis sustaining that the methodological quality of the evidences reported in the papers of Serstè \textit{et al.}\[19\] and Mandorfer \textit{et al.}\[19\] may be too weak for such an important change of treatment in patients with cirrhosis. Indeed a series of flaws can be evidenced and summarized as following: (1) the lack of randomization to the treatment; (2) the retrospective nature of data collection; and (3) the insufficient number of patients included in the final analysis (not always consecutive).

It is noteworthy that patients developing HRS and/or SBP under NSBB therapy are those not totally protected by this class of drugs, in other words, they are clinically non-responders to NSBBs since they develop an event whose risk is reduced by the chronic treatment with NSBBs\[2,3\]. Therefore, this cohort of patients constitutes a highly selected subgroup of cirrhotic patients with high mortality risk if not transplanted. Recently, Leitheahad \textit{et al.}\[23\] conducted an observational study to explore whether or not the treatment by NSBBs increases the mortality risk of patients with an advanced liver disease. The study included a series of 322 consecutive candidates to liver transplant, 117 had refractory ascites. At exception of the window hypothesis, the survival analysis disclosed a significant mortality reduction for patients receiving NSBBs. This occurred in both categories of patients: those without refractory ascites (HR\textsubscript{mortality} $= 0.55$; $95\%$CI: 0.32-0.95), and those with refractory ascites (HR\textsubscript{mortality} $= 0.35$; $95\%$CI: 0.14-0.86). Noteworthy, the survival advantages were achieved even though patients under NSBBs had a low systemic arterial pressure. Moreover, possible selection biases were controlled by matching the population according with the propensity risk score. These results contradict the opinion that NSBBs are detrimental in patients with an advanced or end-stage liver disease. However, Authors fairly state that their patients were highly selected since they were candidates to liver transplantation.

In conclusion: which is the truth? Since its introduction, the evidenced based approach was used to test the efficacy of drugs against hard clinical end-points such as mortality, in order to replace the empiric approach. The randomized controlled trial (RCT) is the best tool to minimize confounding factors and effect modifiers behind the apparent association between an exposure (\textit{e.g.}, treatment with NSBBs) and an effect (mortality) in a specific clinical setting (patients with advanced liver disease).

The studies supporting the “window hypothesis” challenge a huge amount of papers that consistently demonstrated the beneficial effect of NSBBs in patients with PHT. Therefore, it is now mandatory solving any doubts on the safety of such class of drugs in patients with advanced cirrhosis. This aim should be pursued by a trial including a sufficient number of patients on chronic NSBBs therapy with advanced cirrhosis, such as patients with SBP. The effects of the NSBBs would be compared randomizing these patients to stopping or not the chronic treatment with NSBBs. The preference of patients with SBP for such a trial would be justified by the relatively homogeneity of these patients ensured by objective criteria of diagnosis and high risk of renal failure. Certainly this kind of RCT is demanding, and needs a multicenter cooperation. However, the evidence we will obtain is essential before closing (or not) the window.

\section*{REFERENCES}

1. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. \textit{N Engl J Med} 1981; 305: 1371-1374

2. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. \textit{Hepatology} 2003; 37: 902-908 [PMID: 12668985 DOI: 10.1053/jhep.2003.50133]

3. Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. \textit{Am J Gastroenterol} 2006; 101: 506-512 [PMID: 16542287 DOI: 10.1111/j.1572-0241.2006.00453.x]

4. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makueh R. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. \textit{N Engl J Med} 2005; 353: 2254-2261 [PMID: 16306522 DOI: 10.1056/NEJMoa044456]

5. Merkel C, Marin R, Angelii P, Zanella P, Felder M, Bernardinllo E, Cavallarin G, Bolognesi M, Donada C, Bellini B, Torboli P, Gatta A. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. \textit{Gastroenterology} 2004; 127: 476-484 [PMID: 15300580 DOI: 10.1053/j.gastro.2004.05.004]

6. Hernández-Geva V, Arciil C, Colomo A, Garapea I, Poca M, Torras X, Miñana J, Guaner C, Villanueva C. Development of ascites in compensated cirrhosis with severe portal hypertension treated with \textit{β}-blockers. \textit{Am J Gastroenterol} 2012; 107: 418-427 [PMID: 22334252 DOI: 10.1038/ajg.2011.456]

7. Glud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. \textit{J Hepatol} 2007; 46: 734-742 [PMID: 17316871 DOI: 10.1016/j.jhep.2007.01.003]

8. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. \textit{Nat Rev Gastroenterol Hepatol} 2009; 6: 573-582 [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149]

9. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there
are many (stages) where before there was one: In search of a pathophysiologic classification of cirrhosis. *Hepatology* 2010; 51: 1445-1449 [PMID: 20077563 DOI: 10.1002/hep.23478]

10. **D’Amico G**, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; 44: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]

11. **Poynaud T**, Calès P, Pasta L, Idoe G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. *Franco-Italian Multicenter Study Group*. *N Engl J Med* 1991; 324: 1532-1538 [PMID: 1674104 DOI: 10.1056/NEJM199110303242202]

12. **Schier RW**, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodès J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988; 8: 1151-1157 [PMID: 2971015 DOI: 10.1002/hep.1840080532]

13. **Thalheimer U**, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. *Gastroenterology* 2007; 133: 2029-2036 [PMID: 18054573 DOI: 10.1053/j.gastro.2007.10.028]

14. **Reiberger T**, Fertlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. *J Hepatol* 2013; 58: 911-921 [PMID: 2362249 DOI: 10.1016/j.jhep.2012.12.011]

15. **Senzolo M**, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. *Liver Int* 2009; 29: 1189-1193 [PMID: 19508620 DOI: 10.1111/j.1478-3231.2009.02038.x]

16. **Sersté T**, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, Lebrec D. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology* 2010; 52: 1017-1022 [PMID: 20583214 DOI: 10.1002/hep.23775]

17. **Sersté T**, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. *J Hepatol* 2011; 55: 794-799 [PMID: 21354230 DOI: 10.1016/j.jhep.2011.01.034]

18. **Mandorfer M**, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagemann M, Blacky A, Fertlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. *Gastroenterology* 2014; 146: 1680-90.e1 [PMID: 24631577 DOI: 10.1053/j.gastro.2014.03.005]

19. **Krag A**, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. *Gut* 2012; 61: 967-969 [PMID: 22234982 DOI: 10.1136/gutjnl-2011-301348]

20. **Ruiz-del-Arbol L**, Urman J, Fernández I, González M, Navasa M, Monescillo A, Albillos A, Jiménez W, Arroyo V. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. *Hepatology* 2003; 38: 1210-1218 [PMID: 14578859 DOI: 10.1053/jhep.2003.05.0447]

21. **Wong F**, Salerno F. Beta-blockers in cirrhosis: friend and foe? *Hepatology* 2010; 52: 811-813 [PMID: 20812354 DOI: 10.1002/hep.23852]

22. **Leithead JA**, Rajoiriya N, Tahani N, Hodson J, Gunson BK, Tripathi D, Fergusson JW. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. *Gut* 2014; Epub ahead of print [PMID: 25281417 DOI: 10.1136/gutjnl-2013-306502]

**P- Reviewer:** Chen WX, Maruyama H, Rodriguez-Castro KI, Sargsyants N

**S- Editor:** Qi Y

**L- Editor:** A

**E- Editor:** Zhang DN
